Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H21N |
Molecular Weight | 179.3018 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC12CC3CC(C)(C1)CC(N)(C3)C2
InChI
InChIKey=BUGYDGFZZOZRHP-UHFFFAOYSA-N
InChI=1S/C12H21N/c1-10-3-9-4-11(2,6-10)8-12(13,5-9)7-10/h9H,3-8,13H2,1-2H3
Molecular Formula | C12H21N |
Molecular Weight | 179.3018 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021487s010s012s014,021627s008lbl.pdfCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9120573
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021487s010s012s014,021627s008lbl.pdf
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/9120573
NAMENDA (marketed under the brands Namenda among others) is an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimer’s disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimer’s disease. Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca2+, Na+ or K+ channels. Memantine also showed antagonistic effects at the 5HT3 receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency. In vitro studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/?term=15717010
Curator's Comment: Memantine was first synthesized by Eli Lilly and Company and patented in 1968, as documented in the Merck Index, as a derivative of amantadine, an anti-influenza agent.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9120573 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NAMENDA Approved UseNamenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type. Launch Date1.0662624E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.34 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
19.69 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg 14 times / 2 weeks multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1853 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
386.37 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg 14 times / 2 weeks multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
540 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
62 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
64.57 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg 14 times / 2 weeks multiple, oral dose: 5 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
66.86 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18498913 |
5 mg single, oral dose: 5 mg route of administration: Oral experiment type: SINGLE co-administered: |
MEMANTINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Other AEs: Restlessness, Psychosis... Other AEs: Restlessness (1 patient) Sources: Psychosis (1 patient) Visual hallucinations (1 patient) Somnolence (1 patient) Stupor (1 patient) Loss of consciousness (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Loss of consciousness | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Psychosis | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Restlessness | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Somnolence | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Stupor | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Visual hallucinations | 1 patient | 400 mg single, oral Highest studied dose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: |
unhealthy, adult n = 1 Health Status: unhealthy Age Group: adult Population Size: 1 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-487_Namenda_Bioeqr_P1.pdf#page=12 Page: 12.0 |
no | |||
yes [Ki 236 uM] | ||||
yes [Ki 3.7 uM] | ||||
yes [Ki 7.3 uM] |
Drug as victim
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-487_Namenda_Pharmr_P1.pdf#page=16 Page: 16.0 |
PubMed
Title | Date | PubMed |
---|---|---|
[Memantine and neurogenic bladder disorders within the bounds of spastic conditions]. | 1982 |
|
Susceptibility of primary human glial fibrillary acidic protein-positive brain cells to human immunodeficiency virus infection in vitro: anti-HIV activity of memantine. | 1991 Jan |
|
gp120 of HIV-1 induces apoptosis in rat cortical cell cultures: prevention by memantine. | 1992 Jul 1 |
|
Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. | 1996 Oct |
|
How to overcome resistance of influenza A viruses against adamantane derivatives. | 1998 Feb |
|
Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced by cocaine. | 1999 May |
|
Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. | 2000 Jan 28 |
|
Uncompetitive antagonists of the N-methyl-D-aspartate (NMDA) receptors alter the mRNA expression of proteins associated with the NMDA receptor complex. | 2001 Feb |
|
NMDA antagonists inhibit the development of ethanol dependence in rats. | 2001 Jan-Feb |
|
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). | 2002 Nov |
|
Exacerbation of Lewy bodies dementia due to memantine. | 2005 Dec |
|
Memantine alleviates toxicity induced by dichlorvos in rats. | 2005 Mar |
|
Memantine: a review of its use in Alzheimer's disease. | 2006 |
|
Exacerbation of myoclonus by memantine in a patient with Alzheimer disease. | 2007 Aug |
|
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. | 2007 Mar |
|
Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases. | 2007 May |
|
[Therapy of Alzheimer's disease: current status and future development]. | 2008 |
|
Memantine-induced hepatitis with cholestasis in a very elderly patient. | 2008 Apr 15 |
|
Memantine and NMDA antagonism for chronic migraine: a potentially novel therapeutic approach? | 2008 Feb |
|
Methylmercury increases N-methyl-D-aspartate receptors on human SH-SY 5Y neuroblastoma cells leading to neurotoxicity. | 2008 Jul 30 |
|
Galantamine-induced pisa syndrome: memantine as an alternative. | 2008 Jun |
|
Memantine-induced myoclonus and delirium exacerbated by trimethoprim. | 2008 Mar |
|
Does memantine induce bradycardia? A study in the French PharmacoVigilance Database. | 2008 Sep |
|
Memanti-nium chloride 0.1-hydrate. | 2009 Aug 19 |
|
Role of N-methyl-D-aspartate receptors in polychlorinated biphenyl mediated neurotoxicity. | 2009 Jan 10 |
|
Characteristic effects of anti-dementia drugs on rat sleep patterns. | 2009 Mar |
|
[Effects of electroacupuncture on expression of Abeta positive cells of the hippocampus and SOD activity in rats with streptozocin-Alzheimer's disease]. | 2010 Dec |
|
Memantine ameliorates scopolamine-induced amnesia in chicks trained on taste-avoidance learning. | 2010 May |
|
Protective effects of memantine and epicatechin on catechol-induced toxicity on Müller cells in vitro. | 2010 May 27 |
|
Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. | 2010 Nov |
|
Sensitive and rapid HPLC method for determination of memantine in human plasma using OPA derivatization and fluorescence detection: application to pharmacokinetic studies. | 2010 Oct-Dec |
|
Memantine prevents aluminum-induced cognitive deficit in rats. | 2011 Nov 20 |
|
Memantine in patients with moderate to severe Alzheimer's disease: meta-analyses using realistic definitions of response. | 2014 |
Sample Use Guides
Initial dose is 5 mg once daily. Increase dose in 5 mg increments to a maintenance dose of 10 mg twice daily. A minimum of 1 week of treatment with the previous dose should be observed before increasing the dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19948208
Neuronal SK-N-SH cells were treated with 10 uM memantine and was measured levels of secreted total A beta precursor protein APP (sAPP), APP alpha isoform and A beta((1-40)) in a time dependent manner for up to 24h. Memantine significantly decreased the levels of the secreted form of sAPP, sAPP alpha and A beta((1-40)) compared to vehicle treated cells.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:27:53 UTC 2023
by
admin
on
Wed Jul 05 23:27:53 UTC 2023
|
Record UNII |
W8O17SJF3T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
NDF-RT |
N0000020015
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
NCI_THESAURUS |
C38149
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
WHO-ATC |
N06DX01
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
WHO-ATC |
N06DA52
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
WHO-VATC |
QN06DA52
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
NDF-RT |
N0000175745
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
WHO-VATC |
QN06DX01
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
LIVERTOX |
NBK547981
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
WHO-ATC |
N06DA53
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
NDF-RT |
N0000020015
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
NEMDATINE (AUTHORIZED: ALZHEIMER DISEASE)
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
W8O17SJF3T
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
100000085447
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
6719
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | RxNorm | ||
|
3952
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
19982-08-2
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
DTXSID5045174
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
7327
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
4253
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
C73269
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
NCT03527472
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (ClearMEMory) | ||
|
4054
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
1679
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
757843
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
SUB08731MIG
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
W8O17SJF3T
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
DB01043
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
MEMANTINE
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
M7167
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | Merck Index | ||
|
D008559
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
CHEMBL807
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY | |||
|
64312
Created by
admin on Wed Jul 05 23:27:53 UTC 2023 , Edited by admin on Wed Jul 05 23:27:53 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> AGONIST |
ALZHEIMERS DISEASE DRUG ANTAGONIZING NMDA RECEPTOR, ANTAGONISM OF .ALPHA.7 NACHR IS A SIDE PATHWAY.
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
AMOUNT EXCRETED
URINE
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||
Biological Half-life | PHARMACOKINETIC |
|
Elimination PHARMACOKINETIC |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||